Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GSK immunotherapy

- PMLiVE

Novavax’s updated COVID-19 vaccine approved by FDA for emergency use

Individuals aged 12 years and older will be eligible to receive the company's updated vaccine

Biogen Idec building

Biogen’s Actemra biosimilar approved by FDA to treat adult and paediatric arthritis

Tofidence is now the first biosimilar referencing Actemra to gain approval from the US regulator

regeneron headquarters

Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma

The regulator is expected to make a decision on the drug by the end of March 2024

- PMLiVE

GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

- PMLiVE

FDA boosts collaboration with manufacturers to overcome ongoing cancer drug shortages

The supply of cisplatin, carboplatin and methotrexate has nearly halved in the past year

- PMLiVE

Alnylam’s patisiran backed by FDA advisory committee for ATTR cardiomyopathy

Treatment options for the underdiagnosed and rapidly progressive condition are currently limited

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

The neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links